Summary
Pharma Mar SA Pharma Mar is a biopharmaceutical company that discovers, develops and markets marinederived drugs to treat cancer. The company's marketed product Yondelis trabectedin, a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar's developmental pipeline includes Aplidin plitidepsin for multiple myeloma and Tcell lymphoma; PM1183 lurbinectedin for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.Pharma Mar SA PHM Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.
GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.
...